-
Inhibitory Effect of Serotonin Antagonist on Leukocyte-Endothelial Interactions In Vivo and In Vitro.
PloS one 20160101
-
Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice.
PloS one 20160101
-
Beneficial Effects of Sarpogrelate and Rosuvastatin in High Fat Diet/Streptozotocin-Induced Nephropathy in Mice.
PloS one 20160101
-
Sarpogrelate hydrochloride, a serotonin 5HT2A receptor antagonist, ameliorates the development of chronic hypoxic pulmonary hypertension in rats.
Journal of anesthesia 20151001
-
Effects of serotonin on expression of the LDL receptor family member LR11 and 7-ketocholesterol-induced apoptosis in human vascular smooth muscle cells.
Biochemical and biophysical research communications 20140418
-
Selective inhibition of cytochrome P450 2D6 by Sarpogrelate and its active metabolite, M-1, in human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 20140101
-
A 5-hydroxytryptamine receptor antagonist, sarpogrelate, reduces renal tubulointerstitial fibrosis by suppressing PAI-1.
American journal of physiology. Renal physiology 20131215
-
Glucuronidation of a sarpogrelate active metabolite is mediated by UDP-glucuronosyltransferases 1A4, 1A9, and 2B4.
Drug metabolism and disposition: the biological fate of chemicals 20130801
-
Sarpogrelate inhibits the expression of ICAM-1 and monocyte-endothelial adhesion induced by high glucose in human endothelial cells.
Molecular and cellular biochemistry 20130101
-
Suppression of high lipid diet induced by atherosclerosis sarpogrelate.
Journal of cellular and molecular medicine 20121001
-
Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis.
The Journal of dermatology 20120601
-
Role of serotonin in angiogenesis: induction of angiogenesis by sarpogrelate via endothelial 5-HT1B/Akt/eNOS pathway in diabetic mice.
Atherosclerosis 20120201
-
Evaluation of the effectiveness of sarpogrelate on the surrogate markers for macrovascular complications in patients with type 2 diabetes.
Endocrine journal 20120101
-
Serotonin potentiates high-glucose-induced endothelial injury: the role of serotonin and 5-HT(2A) receptors in promoting thrombosis in diabetes.
Journal of pharmacological sciences 20120101
-
Mechanism of inverse agonist action of sarpogrelate at the constitutively active mutant of human 5-HT2A receptor revealed by molecular modeling.
Biological & pharmaceutical bulletin 20120101
-
Effects of additional treatment of sarpogrelate to aspirin therapy on platelet aggregation and plasma plasminogen activator inhibitor activity in patients with stable effort angina.
Thrombosis research 20111201
-
Characteristics of the actions by which 5-HT affects electrical and mechanical activities in rabbit jugular vein.
British journal of pharmacology 20111001
-
Sarpogrelate protects against high glucose-induced endothelial dysfunction and oxidative stress.
International journal of cardiology 20110317
-
Mechanism of sarpogrelate action in improving cardiac function in diabetes.
Journal of cardiovascular pharmacology and therapeutics 20110101
-
Relative contributions of 5-hydroxytryptamine (5-HT) receptor subtypes in 5-HT-induced vasoconstriction of the distended human saphenous vein as a coronary artery bypass graft.
Biological & pharmaceutical bulletin 20110101
-
Validated LC-MS/MS method for the determination of sarpogrelate in human plasma: application to a pharmacokinetic and bioequivalence study in Chinese volunteers.
Journal of pharmaceutical and biomedical analysis 20101102
-
Liquid chromatography tandem mass spectrometry method for the quantification of sarpogrelate, a selective 5-HT(₂A) receptor antagonist, in plasma: application to a pre-clinical pharmacokinetic study.
Biomedical chromatography : BMC 20101101
-
Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention.
Journal of cellular and molecular medicine 20101001
-
Erythrocyte-protective effect of sarpogrelate hydrochloride (Anplag ®), a selective 5-HT2 receptor antagonist: an in vitro study.
Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs 20100901
-
Comparison of antiplatelet potency of sarpogrelate, aspirin, and beraprost in healthy volunteers according to in-vitro closure time.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20100401
-
Sarpogrelate hydrochloride, a selective 5-hydroxytryptamine(2A) antagonist, augments autologous bone marrow mononuclear cell implantation-induced improvement in endothelium-dependent vasodilation in patients with critical limb ischemia.
Journal of cardiovascular pharmacology 20100101
-
Development of sarpogrelate external preparation for intractable pain control. I. Pre-formulation study on application of modified beta-cyclodextrins.
Chemical & pharmaceutical bulletin 20100101
-
Case of livedoid vasculopathy with peripheral neuropathy successfully treated with low-dose warfarin.
The Journal of dermatology 20100101
-
Study design of SEASON registry: prospective Surveillance of cardiovascular Events in an Antiplatelet-treated arterioSclerosis Obliterans patients in JapaN )SEASON).
International heart journal 20100101
-
The prevention of contrast induced nephropathy by sarpogrelate in patients with chronic kidney disease: a study protocol for a prospective randomized controlled clinical trial.
Trials 20100101
-
Chronic treatment of hydroxytryptamine type 2a receptor antagonist sarpogrelate hydrochloride modulates the vasoreactivity of serotonin in experimental rabbit vein grafts.
Journal of vascular surgery 20090901
-
Sarpogrelate versus aspirin in secondary prevention of cerebral infarction: differential efficacy in diabetes? Subgroup analysis from S-ACCESS.
Stroke 20090801
-
Assessment of binding affinity to 5-hydroxytryptamine 2A (5-HT2A) receptor and inverse agonist activity of naftidrofuryl: comparison with those of sarpogrelate.
Journal of pharmacological sciences 20090801
-
Acute effects of sarpogrelate, a 5-HT2A receptor antagonist on cytokine production in endotoxin shock model of rats.
European journal of pharmacology 20090701
-
Sarpogrelate hydrochloride reduced intimal hyperplasia in experimental rabbit vein graft.
Journal of vascular surgery 20090501
-
Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice.
Endocrine research 20090101
-
Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial.
Stroke 20080601
-
Comparison of sarpogrelate and ticlopidine in bare metal coronary stent implantation.
International journal of cardiology 20080507
-
Blockade of serotonin 2A receptor improves glomerular endothelial function in rats with streptozotocin-induced diabetic nephropathy.
Clinical and experimental nephrology 20080401
-
New therapeutic approach for impaired arteriogenesis in diabetic mouse hindlimb ischemia.
Circulation journal : official journal of the Japanese Circulation Society 20080401
-
Antiplatelet therapy mitigates cardiac remodeling and dysfunction in congestive heart failure due to myocardial infarction.
Canadian journal of physiology and pharmacology 20080401
-
Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes.
Clinical journal of the American Society of Nephrology : CJASN 20080301
-
The effects of a 5-HT2A receptor antagonist on blood flow in lumbar disc herniation: application of nucleus pulposus in a canine model.
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society 20080201
-
Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality.
Cardiovascular toxicology 20080101
-
Identification of a key amino acid of the human 5-HT(2B) serotonin receptor important for sarpogrelate binding.
Journal of pharmacological sciences 20070701
-
Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease.
Journal of cardiovascular pharmacology 20070401
-
Synthesis and 5-HT2A, 5-HT1A and alpha1-binding affinities of 2-[2-Hydroxy-3-(pyridin-3-yl-methyl)amino]-, 2-[2-hydroxy-3-(2-pyridin-2-yl-ethyl)amino]- and 2-[2-hydroxy-3-(4-N-methyl-piperazin-1-yl)-amino]propoxybenzaldehyde-O-(substituted) benzyl oximes.
Archiv der Pharmazie 20070301
-
Sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, attenuates neurogenic pain induced by nucleus pulposus in rats.
Spine 20070201
-
Marked improvement with sildenafil in a patient with idiopathic pulmonary arterial hypertension unresponsive to beraprost and sarpogrelate.
Internal medicine (Tokyo, Japan) 20070101
-
Effect of sarpogrelate, a 5-HT(2A) antagonist, on platelet aggregation in patients with ischemic stroke: clinical-pharmacological dose-response study.
Cerebrovascular diseases (Basel, Switzerland) 20070101
-
Increased hypothalamic 5-HT2A receptor gene expression and effects of pharmacologic 5-HT2A receptor inactivation in obese Ay mice.
Biochemical and biophysical research communications 20061229
-
Persistent insulin-sensitizing effects of sarpogrelate hydrochloride, a serotonin 2A receptor antagonist, in patients with peripheral arterial disease.
Circulation journal : official journal of the Japanese Circulation Society 20061101
-
Induction of indefinite survival of fully mismatched cardiac allografts and generation of regulatory cells by sarpogrelate hydrochloride.
Transplantation 20061027
-
Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor.
Journal of pharmacological sciences 20061001
-
5-HT2 receptor blocker sarpogrelate prevents downregulation of antiapoptotic protein Bcl-2 and protects the heart against ischemia-reperfusion injury.
Life sciences 20060927
-
Combined treatment of sustained-release basic fibroblast growth factor and sarpogrelate enhances collateral blood flow effectively in rabbit hindlimb ischemia.
Circulation journal : official journal of the Japanese Circulation Society 20060901
-
Identification of amino acid residues important for sarpogrelate binding to the human 5-hydroxytryptamine2A serotonin receptor.
Journal of pharmacological sciences 20060901
-
Site-directed mutagenesis of the serotonin 5-Hydroxytryptamine2c receptor: identification of amino acids responsible for sarpogrelate binding.
Biological & pharmaceutical bulletin 20060801
-
[Effect of sarpogrelate in enteral feeding of patients with gastroesophageal reflux (GER)].
Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20060701
-
Homology modelling of the serotoninergic 5-HT2c receptor.
Journal of enzyme inhibition and medicinal chemistry 20060601
-
Peripheral 5-HT2A receptor antagonism attenuates primary thermal hyperalgesia and secondary mechanical allodynia after thermal injury in rats.
Pain 20060501
-
Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study.
Vascular medicine (London, England) 20060501
-
A new method for assessment of an anti-5HT(2A) agent, sarpogrelate hydrochloride, on platelet aggregation.
Journal of thrombosis and haemostasis : JTH 20060201
-
Effects of sarpogrelate hydrochloride in a patient with chronic graft-versus-host disease: a case report.
American journal of hematology 20060201
-
Inhibition of 5-hydroxytryptamine receptor prevents occlusive thrombus formation on neointima of the rabbit femoral artery.
Journal of thrombosis and haemostasis : JTH 20060101
-
Sarpogrelate hydrochloride, an antagonist of 5-hydroxytryptamine receptor, improves skin flap survival and suppresses thrombus formation in injured microvessels of rabbits.
Journal of reconstructive microsurgery 20060101
-
The 5-hydroxytryptamine2A receptor antagonist sarpogrelate hydrochloride inhibits acute platelet aggregation in injured endothelium.
The Journal of international medical research 20060101
-
Livedo racemosa as a cutaneous manifestation of polycythemia vera.
European journal of dermatology : EJD 20060101
-
Contribution of the peripheral 5-HT 2A receptor to mechanical hyperalgesia in a rat model of neuropathic pain.
Neurochemistry international 20051101
-
5-HT2A receptor antagonist increases circulating adiponectin in patients with type 2 diabetes.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20050901
-
Effects of a 5-HT2A receptor antagonist, sarpogrelate on thermal or inflammatory pain.
European journal of pharmacology 20050523
-
New treatment of lumbar disc herniation involving 5-hydroxytryptamine2A receptor inhibitor: a randomized controlled trial.
Journal of neurosurgery. Spine 20050401
-
Protective effects of sarpogrelate, a 5-HT2A antagonist, against postischemic myocardial dysfunction in guinea-pig hearts.
Molecular and cellular biochemistry 20050401
-
Selective blockade of serotonin 5-HT2A receptor increases coronary blood flow via augmented cardiac nitric oxide release through 5-HT1B receptor in hypoperfused canine hearts.
Journal of molecular and cellular cardiology 20041201
-
Effects of 5-HT2A receptor antagonist on blood flow in chronically compressed nerve roots.
Journal of the peripheral nervous system : JPNS 20041201
-
Sarpogrelate: cardiovascular and renal clinical potential.
Expert opinion on investigational drugs 20040701
-
Effect of sarpogrelate hydrochloride, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a type 2 diabetic rat model.
Journal of cardiovascular pharmacology 20040201
-
Sarpogrelate, a 5-HT2 receptor blocker, may have a preconditioning-like effect in patients with coronary artery disease.
Circulation journal : official journal of the Japanese Circulation Society 20040101
-
Therapeutic potentials of sarpogrelate in cardiovascular disease.
Cardiovascular drug reviews 20040101
-
Effect of the serotonin blocker sarpogrelate on circulating interleukin-18 levels in patients with diabetes and arteriosclerosis obliterans.
The Journal of international medical research 20040101
-
Electroencephalographical effects of sarpogrelate hydrochloride versus ticlopidine hydrochloride in elderly patients with peripheral atherosclerosis.
The Journal of international medical research 20040101
-
Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats.
Cardiovascular research 20031201
-
Attenuation of the serotonin-induced increase in intracellular calcium in rat aortic smooth muscle cells by sarpogrelate.
Canadian journal of physiology and pharmacology 20031101
-
[Molecular pharmacology of sarpogrelate].
Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20031101
-
A novel serotonin blocker, sarpogrelate, increases circulating adiponectin levels in diabetic patients with arteriosclerosis obliterans.
Diabetes care 20030801
-
Effect of sarpogrelate on altered STZ-diabetes induced cardiovascular responses to 5-hydroxytryptamine in rats.
Molecular and cellular biochemistry 20030701
-
Efficacy of serotonin receptor blocker for symptomatic lumbar disc herniation.
Clinical orthopaedics and related research 20030601
-
Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modeling.
Life sciences 20030530
-
The role of 5-HT on the cardiovascular and renal systems and the clinical potential of 5-HT modulation.
Expert opinion on investigational drugs 20030501
-
Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism.
Atherosclerosis 20030501
-
Effect of MCI-9042, a 5-HT2 receptor antagonist, on retinal ganglion cell death and retinal ischemia.
Experimental eye research 20030401
-
Sarpogrelate treatment reduces restenosis after coronary stenting.
American heart journal 20030301
-
The effects of vasodilators on the relaxation of guinea-pig aorta during acute recoil.
International journal of cardiology 20021201
-
Sarpogrelate hydrochloride, a serotonin2A receptor antagonist, reduces albuminuria in diabetic patients with early-stage diabetic nephropathy.
Diabetes research and clinical practice 20021101
-
The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2 receptor blocker, in rabbit hearts.
Journal of the American College of Cardiology 20021002
-
5-HT2A receptor subtype in the peripheral branch of sensory fibers is involved in the potentiation of inflammatory pain in rats.
Pain 20020901
-
Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with angina pectoris.
American heart journal 20020801
-
Effects of sarpogrelate, a novel 5-HT2 antagonist, on 5-HT-induced endothelium-dependent relaxations in porcine coronary artery.
Japanese journal of pharmacology 20020801
-
Binding and functional affinity of sarpogrelate, its metabolite m-1 and ketanserin for human recombinant alpha-1-adrenoceptor subtypes.
Pharmacology 20020501
-
DOI, a 5-HT2 receptor agonist, induces renal vasodilation via nitric oxide in anesthetized dogs.
European journal of pharmacology 20020215
-
Effects of chronic administration of sarpogrelate on systolic blood pressure of spontaneously hypertensive rats: comparison with quinapril.
Pharmacology 20020201
-
Involvement of rho-kinase in agonists-induced contractions of arteriosclerotic human arteries.
Arteriosclerosis, thrombosis, and vascular biology 20020201
-
Sarpogrelate, a specific 5HT2-receptor antagonist, improves the coronary microcirculation in coronary artery disease.
Clinical cardiology 20020101
-
[Pharmacological analysis of inhibitory effect of sarpogrelate hydrochloride on human radial artery contraction].
[Hokkaido igaku zasshi] The Hokkaido journal of medical science 20020101
-
Blockade of 5-HT(2A) receptors by sarpogrelate protects the heart against myocardial infarction in rats.
Journal of cardiovascular pharmacology and therapeutics 20020101
-
[Involvement of peripheral 5-HT2A receptor activation in inflammatory pain].
Nihon rinsho. Japanese journal of clinical medicine 20010901
-
Sarpogrelate diminishes changes in energy stores and ultrastructure of the ischemic-reperfused rat heart.
Canadian journal of physiology and pharmacology 20010901
-
Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20010701
-
Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: implications for long-term graft patency.
The Annals of thoracic surgery 20010601
-
Monocyte chemotactic protein 1 amplifies serotonin-induced vascular smooth muscle cell proliferation.
Journal of vascular research 20010101
-
The effects of sarpogrelate on cardiomyocyte hypertrophy.
Life sciences 20001103
-
Binding affinity of sarpogrelate, a new antiplatelet agent, and its metabolite for serotonin receptor subtypes.
Archives internationales de pharmacodynamie et de therapie 19960101
-
In-vitro pharmacology of sarpogrelate and the enantiomers of its major metabolite: 5-HT2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contractions in rat tail artery.
The Journal of pharmacy and pharmacology 19950401
-
Binding of [3H]haloperidol to dopamine D2 receptors in the rat striatum.
The Journal of pharmacy and pharmacology 19921101
